Journal
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Volume 1482, Issue 1, Pages 213-224Publisher
WILEY
DOI: 10.1111/nyas.14508
Keywords
esophageal squamous cell carcinoma; multidisciplinary treatment; neoadjuvant chemoradiotherapy; neoadjuvant chemotherapy; neoadjuvant immunotherapy
Categories
Funding
- Program of Science and Technology of Sichuan Province [2018SZ0199]
- International Cooperation Projects of Science and Technology of Sichuan Province [2020YFH0169]
Ask authors/readers for more resources
Esophageal squamous cell carcinoma (ESCC) is one of the most common malignancies worldwide, especially in East Asia. ESCC accounts for more than 90% of esophageal cancer. Currently, neoadjuvant therapy in combination with surgical resection is the mainstay of treatment. However, the overall survival rate of patients with locally advanced ESCC is not satisfactory even when treated following the standard treatment guidelines. With neoadjuvant chemoradiotherapy, chemotherapy, or emerging immunotherapy, continuous exploration of efficacy in relation to ESCC is expected to improve overall survival further. Here, we review and summarize current evidence for efficacy of preoperative therapy for locally advanced ESCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available